BELGRADE, MT , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Xtant Medical Holdings , Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the recent additions of five senior sales executives: Dana Lyons , Vice

BELGRADE, MT , Jan. 11, 2019 (GLOBE NEWSWIRE) -- Xtant Medical Holdings , Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the appointment of Ronald Berlin as Vice President & Chief Operations

BELGRADE, MT , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the third quarter ended September 30, 2018 .

BELGRADE, MT , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarter and year to date ended September 30,

BELGRADE, MT , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the appointment of Michael Mainelli to serve as Interim Chief Executive

BELGRADE, MT, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine products and medical devices, today announced it has executed amendments to its credit facility reducing interest payable, among other provisions. Xtant has also issued warrants for the purchase of 1.2 million shares of common stock. The Company has executed the 24th and 25th amendments to its Amended and Restated Cred…

BELGRADE, MT, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine products and medical devices, today announced the appointment of Kathie Lenzen as chief financial officer, effective August 20, 2018. Ms. Lenzen will report to Carl O’Connell, Xtant’s chief executive officer. “Ms. Lenzen is an accomplished healthcare executive with significant financial expertise and we are please…

BELGRADE, MT, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the second quarter ended June 30, 2018. Summary of Second Quarter 2018 Financial Highlights and Recent Announcements: Revenue for the second quarter of 2018 was $18.7 million, down from $21.4 million for the second quarter of 2017 Gross Margin for the second qua…

BELGRADE, MT, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announces that it will release its financial results for the quarter ended June 30, 2018, after the close of the financial markets on Tuesday, August 7, 2018. An accompanying conference call will be conducted by Carl O'Connell, chief executive officer, and Laura Kendall, interim chief financial officer, to …

BELGRADE, MT, July 10, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Kevin Brandt to the new executive position of Chief Commercial Officer effective July 9, 2018. “We are excited to have such a talented and experienced executive officer join our team,” said Carl O’Connell, chief executive officer of Xtant. “Kevin’s past accomplishments …

BELGRADE, MT, June 19, 2018 (GLOBE NEWSWIRE) -- XtantTM Medical Holdings, Inc. (NYSE American: XTNT) announces that the subscription period for its previously announced rights offering (the “Offering”) of shares of the Company’s common stock at a subscription price of $7.20 per share expired on June 18, 2018, and these rights are no longer exercisable. Based on the review of preliminary results provided by the Company’s subscription agent, Corporate Stock Transfer, Inc., Xtant Medical…

BELGRADE, MT / ACCESSWIRE / May 21, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice™-C Porous Titanium Cervical Interbody System.InTice-C is designed using OsteoSync Ti, a best-in-class, cost-effective, highly porous titanium scaffold material for improved implant fixation. The material more closely resembles the bioscaff…